Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | terminated | Phase 1 | 142 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 21, 2022 | clinicaltrials |
| NCT02052193 | Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | terminated | Phase 2 | 8 | University Hospital TuebingenOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02414750 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma(REPOSIT) | terminated | Phase 2 | 78 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03464604 | Melanoma Accuracy Study; Phase 2 | terminated | — | 121 | Nova Scotia Health AuthorityOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT00945269 | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | terminated | Phase 3 | 481 | Idera Pharmaceuticals, Inc.INDUSTRY | 11 | Nov 8, 2022 | clinicaltrials |
| NCT01810016 | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | terminated | Phase 1 | 8 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 12, 2022 | clinicaltrials |
| NCT01838200 | Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | terminated | Phase 1 | 5 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT00145158 | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma | terminated | Phase 1 / Phase 2 | 23 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00145145 | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02601378 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | terminated | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 29, 2022 | clinicaltrials |
| NCT03301636 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma(NLG2107) | terminated | Phase 2 | 21 | NewLink Genetics CorporationINDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT00507325 | Sample Collection From Melanoma Patients | terminated | — | 131 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | terminated | Early Phase 1 | 6 | Yale UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01744171 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | terminated | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03259425 | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03332589 | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | terminated | Phase 1 | 4 | Spirita Oncology, LLCINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01918930 | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 | terminated | Phase 1 | 6 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | terminated | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | terminated | Phase 3 | 20 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 5 | Jan 19, 2022 | clinicaltrials |
| NCT02818023 | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | terminated | Phase 1 | 9 | Yana NajjarOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT00758797 | A Novel Treatment for Metastatic Melanoma | terminated | Phase 1 | 7 | Northwestern UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy | terminated | — | 98 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2021 | clinicaltrials |
| NCT02009384 | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox | terminated | Phase 2 | 2 | University of LouisvilleOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT02355574 | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results(INTEGRATE) | terminated | — | 301 | Castle Biosciences IncorporatedINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02355587 | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes(EXPAND) | terminated | — | 72 | Castle Biosciences IncorporatedINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT00615160 | PTK/ZK in Disseminated Malignant Melanoma | terminated | Phase 1 / Phase 2 | 9 | Michael WeichenthalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02375984 | A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas(TIL) | terminated | Phase 2 | 1 | Saint John's Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02974803 | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | terminated | Phase 2 | 6 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 241 | Dynavax Technologies CorporationINDUSTRY | 4 | Aug 3, 2021 | clinicaltrials |
| NCT02650492 | Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma | terminated | N/A | 2 | Clinical Laserthermia Systems ABINDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT03394937 | Safety of Intranodal ECI-006 in Melanoma Patients | terminated | Phase 1 | 21 | eTheRNA immunotherapiesINDUSTRY | 2 | Jun 21, 2021 | clinicaltrials |
| NCT02097732 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | terminated | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT04473027 | BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs(BLOOD) | terminated | — | 3 | University Hospital, GhentOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT03224208 | Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients(VECODUE) | terminated | Phase 2 | 9 | Fondazione Melanoma OnlusOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT03724968 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | terminated | Phase 2 | 2 | Elizabeth DavisOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT00961844 | Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma | terminated | Phase 1 / Phase 2 | 15 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03727087 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma | terminated | — | 348 | Exact Sciences CorporationINDUSTRY | 1 | Feb 10, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 21, 2022source: clinicaltrials